Nkarta's Stock Climbs 28% After FDA Approves Drug Application
By Adam L. Cataldo
Nkarta's shares rallied after the company said its investigational new drug application for NKX019, a treatment for lupus nephritis, was approved by the U.S. Food and Drug Administration.
The stock climbed 28% to $1.89 in late morning trading Tuesday. The stock hit a 52-week low of $1.28 earlier this month, and the shares are down 69% this year.
The company said its multi-center, open label, dose escalation clinical trial will assess the safety and clinical activity of NKX019 in patients with refractory lupus nephritis.
Nkarta, a biopharmaceutical company based in South San Francisco, Calif., said it is a developer of engineered natural killer cell therapies.
Lupus nephritis is a form of systemic lupus erythematosus, and is developed by about 40% of the estimated 200,000 people in the U.S. diagnosed with the disease. Of that group, 30% will develop end stage kidney disease, which can be fatal unless they receive dialysis or a kidney transplant.
Write to Adam Cataldo at adam.cataldo@wsj.com.
(END) Dow Jones Newswires
October 17, 2023 11:45 ET (15:45 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits